An Integrative Review to Progress the Responsible Development of Nano-Drugs

Shalini Singh, K. Kanny, G. Redhi
{"title":"An Integrative Review to Progress the Responsible Development of Nano-Drugs","authors":"Shalini Singh, K. Kanny, G. Redhi","doi":"10.51415/ajims.v5i1.1114","DOIUrl":null,"url":null,"abstract":"There has been extensive research on improving and innovating current treatments for irritable-bowel-syndrome using nanotechnology. However, there are growing challenges to progress these drugs to clinical trials and commercialisation. This study sought to develop a framework to manage key features, overlooked in current studies, to improve the development of drugs. An integrative literature review was used to extract themes by using a summative content analysis to interrogate information. Validity was established when saturation of information was achieved. Reliability focussed on the repeatability of key information. Absorption, distribution, metabolism, excretion and toxicity, quality by design attributes, metrology, and standardisation of practice emerged as important themes. These themes together among others, were used to develop the framework to manage the drug development process: Knowledge-based society, Foresight planning, Multidisciplinary approach, Unified definition, Adapt to existing standards and guidelines, Precautionary principle, Case-by-case approach, Quality-by-design, Scale-up and Training. The framework provided reflections that no study has considered. The framework will ensure that drug development will be approached strategically to avoid duplication of research-designs, including risk mitigation, quality at the source and supplier-chain management to progress drug development to clinical trials and beyond.","PeriodicalId":389941,"journal":{"name":"African Journal of Inter/Multidisciplinary Studies","volume":"297 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of Inter/Multidisciplinary Studies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51415/ajims.v5i1.1114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

There has been extensive research on improving and innovating current treatments for irritable-bowel-syndrome using nanotechnology. However, there are growing challenges to progress these drugs to clinical trials and commercialisation. This study sought to develop a framework to manage key features, overlooked in current studies, to improve the development of drugs. An integrative literature review was used to extract themes by using a summative content analysis to interrogate information. Validity was established when saturation of information was achieved. Reliability focussed on the repeatability of key information. Absorption, distribution, metabolism, excretion and toxicity, quality by design attributes, metrology, and standardisation of practice emerged as important themes. These themes together among others, were used to develop the framework to manage the drug development process: Knowledge-based society, Foresight planning, Multidisciplinary approach, Unified definition, Adapt to existing standards and guidelines, Precautionary principle, Case-by-case approach, Quality-by-design, Scale-up and Training. The framework provided reflections that no study has considered. The framework will ensure that drug development will be approached strategically to avoid duplication of research-designs, including risk mitigation, quality at the source and supplier-chain management to progress drug development to clinical trials and beyond.
纳米药物研究进展综述
在利用纳米技术改进和创新目前治疗肠易激综合征的方法方面,已经进行了广泛的研究。然而,将这些药物推进临床试验和商业化面临越来越多的挑战。本研究试图建立一个框架来管理当前研究中被忽视的关键特征,以改善药物的开发。通过总结性内容分析来询问信息,采用综合文献综述来提取主题。当信息达到饱和时,即确定有效性。可靠性侧重于关键信息的可重复性。吸收、分布、代谢、排泄和毒性、设计属性的质量、计量和标准化实践成为重要的主题。这些主题和其他主题一起用于制定管理药物开发过程的框架:知识为基础的社会、前瞻性规划、多学科方法、统一定义、适应现有标准和指南、预防原则、个案处理方法、设计质量、扩大规模和培训。该框架提供了没有研究考虑过的反思。该框架将确保战略性地处理药物开发,以避免重复的研究设计,包括降低风险、源头质量和将药物开发推进到临床试验及以后的供应链管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信